ICOD for scientists

Publications

A strict and efficacious management of the project will guarantee, quality, respect of deadline and of the assigned budget.

The Project Management and the ICOD Dissemination Board together will oversee this communication plan to continuously ensure that the intended information is reaching the target audience in order to maximize the impact of the project. The ICOD Dissemination Board will disseminate the results of ICOD to relevant stakeholders. Audiences targeted by the ICOD project are the general public, the press, the public institutions, the medical & scientific community, the Down syndrome (DS) community, the pharmaceutical industry and investors.

Expected outcomes:

  • Publication of high-profile papers and communications to scientific and biotech meetings that will increase awareness on the use of CB1-SSi and AEF0217 for the treatment of cognitive impairment in neurodevelopmental disorders.
  • Participate in activities of DS associations and general public events that will promote the development of novel treatments for intellectual disabilities.

Articles

Lorenzon N, Musoles-Lleó J, Turrisi F, Gomis-González M, De La Torre R, Dierssen M. State-of-the-art therapy for Down syndrome. Dev Med Child Neurol. 2023 Jul;65(7):870-884. doi: 10.1111/dmcn.15517. (https://pubmed.ncbi.nlm.nih.gov/36692980/).

Happy to share our second publication from the European @ICOD_Project where we demonstrate that low TGF-β1 plasma levels are associated with cognitive decline in Down syndrome and also suggest that rescue of TGF-β1 might represent a new strategy to prevent cognitive decline in DS!

Grasso M, Fidilio A, L'Episcopo F, Recupero M, Barone C, Bacalini MG, Benatti C, Giambirtone MC, Caruso G, Greco D, Di Nuovo S, Romano C, Ferri R, Buono S, Cuello AC, Blom JMC, Tascedda F, Piazza PV, De La Torre R, Caraci F. Low TGF-β1 plasma levels are associated with cognitive decline in Down syndrome. Front Pharmacol. 2024 Mar 21;15:1379965. doi: 10.3389/fphar.2024.1379965. To download the full text go on https://pubmed.ncbi.nlm.nih.gov/38576478/